Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newbold, R. R.
Right arrow Articles by Liehr, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newbold, R. R.
Right arrow Articles by Liehr, J. G.
[Cancer Research 60, 235-237, January 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Induction of Uterine Adenocarcinoma in CD-1 Mice by Catechol Estrogens1

Retha R. Newbold2 and Joachim G. Liehr

Developmental Endocrinology Section, Reproductive Toxicology Group, Laboratory of Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709 [R. R. N.], and Stehlin Foundation for Cancer Research, Houston, Texas 77003 [J. G. L.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Catechol estrogens may mediate estrogen-induced carcinogenesis because 4-hydroxyestradiol induces DNA damage and renal tumors in hamsters, and this metabolite is formed in the kidney and estrogen target tissues by a specific estrogen 4-hydroxylase. We examined the carcinogenic potential of catechol estrogen in an experimental model previously reported to result in a high incidence of uterine adenocarcinoma after neonatal exposure to diethylstilbestrol. Outbred female CD-1 mice were treated with 2- or 4-hydroxyestradiol, 17ß-estradiol, or 17{alpha}-ethinyl estradiol on days 1–5 of neonatal life (2 µg/pup/day) and sacrificed at 12 or 18 months of age. Mice treated with 17ß-estradiol or 17{alpha}-ethinyl estradiol had a total uterine tumor incidence of 7% or 43%, respectively. 2-Hydroxyestradiol induced tumors in 12% of the mice, but 4-hydroxyestradiol was the most carcinogenic estrogen, with a 66% incidence of uterine adenocarcinoma. Both 2- and 4-hydroxylated catechols were estrogenic and increased uterine wet weights in these neonates. These data demonstrate that both 2- and 4-hydroxyestradiol are carcinogenic metabolites. The high tumor incidence induced by 4-hydroxyestradiol supports the postulated role of this metabolite in hormone-associated cancers.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Estradiol induces kidney tumors in Syrian hamsters (1) . This animal model has been examined extensively to elucidate the mechanism of tumorigenesis by this natural hormone (2 , 3) . As part of such a mechanistic study, the induction of renal tumors by catechol estrogens has previously been examined to determine the role of these metabolites in this process. 4-Hydroxyestradiol was as carcinogenic as estradiol in the hamster kidney system, whereas 2-hydroxyestradiol did not induce any tumors (2 , 4 , 5) . The applicability of this finding to human cancers has remained unclear because the hamster kidney is a mechanistic model but not an organ model for the genesis of human hormone-associated cancers, as, for instance, in the breast or uterus. Moreover, the concept of 4-hydroxyestradiol mediating cancer induction by hormones as determined in the hamster kidney system would be further strengthened if validated in another organ model more closely associated with human hormonal cancers.

In this investigation, we examined the carcinogenic activity of 2- and 4-hydroxyestradiol by studying the induction of uterine adenocarcinoma in CD-1 mice treated with either of these estrogen metabolites within the first 5 days of life. Uterine tumors are induced in this rodent strain 12–18 months after treatment with either estradiol or DES3 (6) . This system is thus an excellent model for the study of the mechanism of induction of this neoplasm by hormones. For comparison with previous results, tumors were also induced by the natural hormone estradiol (6) and by the synthetic estrogen 17{alpha}-ethinyl estradiol. In addition, increases in uterine wet weight in the neonatal CD-1 mice were recorded for each of these estrogens to assess the hormonal activity of these compounds under our treatment conditions in the neonates. Our data offer insight into the role of catechol estrogen metabolites in the induction of uterine tumors.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Tumor Induction.
Timed pregnant outbred female CD-1 [Crl: CD-1 (ICR) BR] mice near term were obtained from the breeding colony at National Institute of Environmental Health Sciences (Research Triangle Park, NC). Mice were individually housed in plastic cages with hard wood chip bedding under a 12-h light/12-h dark cycle in a temperature-controlled room (21°C–22°C) and fed NIH 31 mouse chow and fresh water ad libitum. All animal procedures complied with National Institute of Environmental Health Sciences animal care guidelines. At delivery, litters were adjusted to eight female pups/mom. Pups were given daily s.c. injections of 2 µg/pup/day of estrogen (2- or 4-hydroxyestradiol, 17ß-estradiol, or 17{alpha}-ethinyl estradiol; Sigma Chemical Co., St. Louis, MO) dissolved in corn oil or corn oil alone (as a control) on days 1–5 of life. This estrogen dose was chosen because it has previously been shown to result in uterine carcinoma in 90% of aged mice treated with DES on days 1–5 of neonatal life (6) . Mice were weaned at 21 days of age and housed four mice/cage. Mice were sacrificed by cervical dislocation at 12 or 18 months of age. Reproductive tract tissues were removed quickly, fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 6 µm. Tissue sections were stained with H&E and evaluated using light microscopy. If an area of pathological change was observed, additional sections were made for further evaluation. The number of mice with reproductive tract tumors was determined.

Estrogenicity of Catechol Estrogens in Neonatal Mouse.
Pups were given daily s.c. injections of estrogen dissolved in corn oil or corn oil alone (as a control) on days 1–4 of neonatal life. A minimum of 10 pups/compound was used. On the morning of day 5, mice were sacrificed, and body weights and uterine weights were recorded. Data are expressed as the percentage of uterine wet weight increase over values in corn oil-treated control mice.

Statistical Methods.
Comparisons of uterine weights were made by Duncan’s multiple range test (7) . The incidences of uterine adenocarcinoma were compared by Fisher’s exact tests (8) .


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Carcinogenicity of Catechol Estrogens.
Both the catechol estrogens examined, 2- and 4-hydroxyestradiol, induced tumors in the CD-1 mice (Table 1)Citation . 2-Hydroxyestradiol was more carcinogenic than estradiol, with 14% and 11% of the rodents developing uterine adenocarcinoma 12 and 18 months, respectively, after neonatal catechol estrogen administration. In contrast, 4-hydroxyestradiol was considerably more carcinogenic than 2-hydroxyestradiol and produced a 74% (12 months) and 56% (18 months) tumor incidence after treatment in the neonatal period. 17{alpha}-Ethinyl estradiol also induced more tumors (38% at 12 months and 50% at 18 months) than did estradiol. The type of tumor induced was, in all cases, similar to neoplasms produced by DES or estradiol, as described previously (6) . Uterine adenocarcinoma in an 18-month-old mouse treated neonatally on days 1–5 of life with 4-hydroxyestradiol is shown in Fig. 1Citation . The lesion is extensive, with irregularly shaped glands invading through the myometrium to the serosal surface of the uterus. There was a mixed population of squamous, cuboidal, and columnar cells present in this lesion. In another animal, the tumor was composed of neoplastic cells that formed relatively well-defined glandular patterns in some areas, but endometrial glands were crowded together with little intervening stroma in some foci. Some glands contained secretory material, and some were lined by cells that were piling up (Fig. 2Citation ) but many glands appeared to be just nests of cells with no apparent lumen. Mitotic figures were frequently seen in this lesion. These uterine glands invaded through the myometrium to the serosal surface of the tissue. These were typical examples of the uterine tumors observed at this age.


View this table:
[in this window]
[in a new window]

  		Table 1 Induction of uterine adenocarcinoma in CD-1 mice by 2- and 4-hydroxyestradiol

Mice were given s.c. injections of the indicated compound (2 µg/pup/day) on days 1–5 of neonatal life and sacrificed at 12 or 18 months of age. Uterine tissues were examined for evidence of histological alterations using light microscopy. Values are presented as the number of mice with uterine adenocarcinoma/total number of animals and as the percentage of tumor incidence/group (shown in parentheses).

 


View larger version (137K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Well-differentiated invasive uterine adenocarcinoma in an 18-month-old mouse treated neonatally with 4-hydroxyestradiol on days 1–5 of life. Note the extensive lesion with irregularly shaped glands, with little intervening stroma that extend through the myometrium to the serosal surface (arrow). Sample was stained with H&E (x4).

 


View larger version (156K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Uterine carcinoma in an 18-month-old mouse treated neonatally with 4-hydroxyestradiol on days 1–5 of life. Note that the cells are piling up in some glands with an intact basal lamina (arrow), but other areas are invasive within the adjacent stroma. There is much nuclear pleomorphism, and mitotic figures (m) are frequent. Sample was stained with H&E (x20).

 
Hormonal Activity of Catechol Estrogens.
Estradiol and 17{alpha}-ethinyl estradiol induced a 133% and 146% gain in uterine wet weights, respectively, over control values obtained with corn oil-treated animals (Table 2)Citation . 2-Hydroxyestradiol was less estrogenic than estradiol or ethinyl estradiol and produced a 107% increase of uterine wet weights over controls. In contrast, 4-hydroxyestradiol had a higher estrogenic potency in this system than the parent hormone and induced a 213% gain of uterine wet weights in these neonatal mice. These data demonstrate that both catechols are hormonally active estrogens in these neonatal mice.


View this table:
[in this window]
[in a new window]

  		Table 2 Estrogenic potency of 2- and 4-hydroxyestradiol in the neonatal mouse uterus

Mice were given s.c. injections of 2 µg/pup/day of estrogen in corn oil or corn oil alone for controls on days 1–4 of neonatal life. They were sacrificed on day 5, and the uterine weight (wt.)/body wt. ratio was determined. A minimum number of 10 pups/compound were included in each group.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Our data demonstrate the powerful carcinogenic activity of 4-hydroxyestradiol as indicated previously in the hamster kidney tumor model (2 , 4 , 5) . Tumor induction by this estrogen metabolite in the uterine endometrium is relevant to the human situation for the following reason: estrogen administration unopposed by progestin increases uterine cancer risk in humans (9 , 10) . By analogy, estradiol induces uterine adenocarcinoma in mice, which closely resembles the human endometrial neoplasm (6) . Moreover, the predominant metabolic conversion of estradiol in human or rodent uterus is 4-hydroxylation (11 , 12) . The 9-fold higher tumor incidence in mice 12 and 18 months after 4-hydroxyestradiol administration compared to that in the estradiol-treated group supports the previous hypothesis that formation of this catechol estrogen represents a metabolic activation of estradiol to a (precursor of a) reactive intermediate (3 , 13 , 14) . Consistent with this argument, several types of DNA damage are induced in vitro or in vivo by 4-hydroxyestradiol [as reviewed by Yager and Liehr (3) and Liehr (13 , 14) ]. The 60% higher estrogenic potency of 4-hydroxyestradiol compared to estradiol in the neonatal mouse uterus may contribute to tumorigenesis, but it is unlikely to be the sole characteristic of this metabolite necessary for the 9-fold increase in tumorigenesis. It is more likely that tumors are initiated by DNA alteration in combination with receptor-mediated proliferation of damaged cells, as proposed previously (3 , 13 , 14) .

2-Hydroxyestradiol is also more carcinogenic than estradiol in this tumor model and is 80% as hormonally potent as the parent estrogen. Our data provide the first evidence for any carcinogenic activity of this catechol estrogen because it did not induce any tumors in the hamster kidney model (2 , 4 , 5) . 2-Hydroxyestradiol has previously been shown to undergo metabolic redox cycling between quinone and hydroquinone (catechol) forms and to induce various forms of DNA damage (15, 16, 17, 18) . Thus, the induction of uterine tumors in mice by this catechol is consistent with its DNA damaging potential (15, 16, 17, 18) and is inconsistent with a designation as "a good estrogen" or antiestrogen (19 , 20) . The lack of tumor induction by 2-hydroxyestradiol in the hamster kidney system may have been due to rapid conjugation of this estrogen metabolite by catechol-O-methyltransferase, whereas in neonatal mice, this conjugating enzyme activity may not have reached activity levels prevalent in adults and thus may not have detoxified this reactive estrogen.

17{alpha}-Ethinyl estradiol was slightly more estrogenic than estradiol but induced a much higher tumor incidence than the natural hormone (50% and 10% incidence after 18 months, respectively). These data are inconsistent with the hamster kidney system, where this synthetic estrogen is only a poor carcinogen (1 , 2 , 5) . This differential carcinogenic activity may be due to species differences in metabolism. In hamsters, the low carcinogenic activity of 17{alpha}-ethinyl estradiol is consistent with a decreased renal conversion of this synthetic estrogen to catechol metabolites (21) . In contrast, our data in mice on the carcinogenic activity of 17{alpha}-ethinyl estradiol are in line with induction and promotion of liver tumors in rodents by 17{alpha}-ethinyl estradiol (22 , 23) . Moreover, 17{alpha}-ethinyl estradiol is the estrogen used in oral contraceptives and has been reported to raise the risk of breast cancer in humans (24, 25, 26) . Consistent with this concept of breast cancer induction, 4-hydroxylation of estrogens predominates over 2-hydroxylation in human breast cancer by a specific estrogen 4-hydroxylase, that is detectable in tumors and normal mammary tissue (27) .

In summary, these data are the first demonstration of the carcinogenic activity of 2- and 4-hydroxyestradiol in the mouse uterus. Furthermore, the potent carcinogenicity of 4-hydroxyestradiol in the mouse uterus adds support to the hypothesis that this estradiol metabolite plays a role in tumor induction in hormone-associated cancers.


   Acknowledgments
 
We thank Wendy Jefferson and Elizabeth Padilla-Banks (NIEHS, Research Triangle Park, NC) for dedicated and expert technical assistance, Drs. Bill Bullock (Wake Forest University, Winston Salem, NC) and Darlene Dixon (NIEHS) for consultations in pathology, Dr. Joseph Haseman (NIEHS) for statistical analysis, and Georgeann Ward (Stehlin Foundation, Houston, TX) for typing assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH/National Cancer Institute Grant CA 74971 (to J. G. L.). Back

2 To whom requests for reprints should be addressed, at National Institute of Environmental Health Sciences, P. O. Box 12233, Research Triangle Park, NC 27709. Phone: (919) 541-0738; Fax: (919) 541-4634; E-mail: newbold1{at}niehs.nih.gov Back

3 The abbreviation used is: DES, diethylstilbestrol. Back

Received 9/13/99. Accepted 12/ 1/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Kirkman H. Estrogen-induced tumors of the kidney in the Syrian hamster. III. Growth characteristics in the Syrian hamster. Natl. Cancer Inst. Monogr., 1: 1-57, 1959.
  2. Liehr, J. G., and Sirbasku, D. A. Estrogen-dependent kidney tumors. In: M. Taub (ed.), Tissue Culture of Epithelial Cells, pp. 205–234. New York: Plenum, 1985.
  3. Yager J. D., Liehr J. G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 266: 203-232, 1996.
  4. Liehr J. G., Fang W. F., Sirbasku D. A., Ulubelen A. A. Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid Biochem., 24: 353-356, 1986.[Medline]
  5. Li J. J., Li S. A. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed. Proc., 46: 1858-1863, 1987.[Medline]
  6. Newbold R. R., Bullock B. C., McLachlan J. A. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res., 50: 7577-7581, 1990.[Abstract/Free Full Text]
  7. Miller, R. J. Simultaneous Statistical Inference. New York: McGraw Hill, 1966.
  8. Siegel, S. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw Hill, 1956.
  9. Greenwald P., Caputo T. A., Wolfgang P. E. Endometrial cancer after menopausal use of estrogens. Obstet. Gynecol., 50: 239-243, 1977.[Medline]
  10. Siiteri, P. K., Nisker, J. A., and Hammond, G. L. Hormonal basis of risk factors for breast and endometrial cancer. In: S. Iacobelli, R. J. B. King, H. R. Linder, and M. E., Lippman (eds.), Hormones and Cancer, pp. 499–505. New York: Raven, 1980.
  11. Paria B. C., Chakraborty C., Dey S. K. Catechol estrogen formation in mouse uterus and its role in implantation. Mol. Cell. Endocrinol., 69: 25-31, 1990.[Medline]
  12. Liehr J. G., Ricci M. J., Jefcoate C. R., Hannigan E. V., Hokanson J. A., Zhu B. T. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc. Natl. Acad. Sci. USA, 92: 9220-9224, 1995.[Abstract/Free Full Text]
  13. Liehr J. G. Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ. Health Perspect., 105: 565-569, 1997.
  14. Liehr J. G. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur. J. Cancer Prev., 6: 3-10, 1997.[Medline]
  15. Liehr J. G., Ulubelen A. A., Strobel H. W. Cytochrome P450-mediated redox cycling of estrogens. J. Biol. Chem., 261: 16865-16870, 1986.[Abstract/Free Full Text]
  16. Roy D., Strobel H. W., Liehr J. G. Cytochrome b5-mediated redox cycling of estrogen. Arch. Biochem. Biophys., 296: 331-338, 1991.
  17. Li Y., Trush M. A., Yager J. D. DNA damage caused by reactive oxygen species originating from a copper-dependent oxidation of the 2-hydroxy catechol of estradiol. Carcinogenesis (Lond.), 15: 1421-1427, 1993.[Abstract/Free Full Text]
  18. Cavalieri E. L., Stack D. E., Devanesan P. D., Todorovic R., Dwivedy I., Higginbotham S., Johansson S. L., Patil K. D., Gross M. L., Godden J. K., Ramanathan R., Cerny R. L., Rogan E. G. Molecular origin or cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA, 94: 10937-10942, 1997.[Abstract/Free Full Text]
  19. Schneider J., Huh M. M., Bradlow H. L., Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem., 259: 4840-4845, 1984.[Abstract/Free Full Text]
  20. Vandewalle B., Lefebvre J. Opposite effects of estrogen and catechol estrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol. Cell. Endocrinol., 61: 239-246, 1989.[Medline]
  21. Zhu B. T., Roy D., Liehr J. G. The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. Endocrinology, 132: 577-583, 1993.[Abstract/Free Full Text]
  22. Yager J. D., Zurlo J., Ni N. Sex hormones and tumor promotion in liver. Proc. Soc. Exp. Biol. Med., 198: 667-674, 1991.[Medline]
  23. Yager, J. D., and Zurlo, J. Role of estrogens in liver carcinogenesis. In: J. J. Li, S. Nandi, and S. A. Li (eds.), Hormonal Carcinogenesis: Proc. 2nd Int. Symp., . New York: Springer-Verlag, pp. 211–218. Proceedings of the Second International Symposium, 1996.
  24. Henderson B. E., Ross R. K., Pike M. C. Toward the primary prevention of cancer. Science (Washington DC), 244: 1131-1138, 1991.
  25. Hulka B. S., Liu E. T., Lininger R. A. Steroid hormones and risk of breast cancer. Cancer (Phila.), 74: 1111-1124, 1993.[Medline]
  26. Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Manson J. E., Stampfer M. J., Hennekens C., Rosner B., Speizer F. E. The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N. Engl. J. Med., 332: 1589-1593, 1995.[Abstract/Free Full Text]
  27. Liehr J. G., Ricci M. J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. USA, 93: 3294-3296, 1996.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
W. A. Khan, M. Uddin, Mohd. W. A. Khan, and H. S. Chabbra
Catecholoestrogens: possible role in systemic lupus erythematosus
Rheumatology, November 1, 2009; 48(11): 1345 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Saini, H. Hirata, S. Majid, and R. Dahiya
Functional Significance of Cytochrome P450 1B1 in Endometrial Carcinogenesis
Cancer Res., September 1, 2009; 69(17): 7038 - 7045.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. M. Mense, B. Singh, F. Remotti, X. Liu, and H. K. Bhat
Vitamin C and {alpha}-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats
Carcinogenesis, July 1, 2009; 30(7): 1202 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. N. Timofeeva, S. Kropp, W. Sauter, L. Beckmann, A. Rosenberger, T. Illig, B. Jager, K. Mittelstrass, H. Dienemann, The LUCY-Consortium, et al.
CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences
Carcinogenesis, July 1, 2009; 30(7): 1161 - 1169.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
B. Wihlen, S. Ahmed, J. Inzunza, and J. Matthews
Estrogen Receptor Subtype- and Promoter-Specific Modulation of Aryl Hydrocarbon Receptor-Dependent Transcription
Mol. Cancer Res., June 1, 2009; 7(6): 977 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-A. Park, H.-K. Na, E.-H. Kim, Y.-N. Cha, and Y.-J. Surh
4-Hydroxyestradiol Induces Anchorage-Independent Growth of Human Mammary Epithelial Cells via Activation of I{kappa}B Kinase: Potential Role of Reactive Oxygen Species
Cancer Res., March 15, 2009; 69(6): 2416 - 2424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. L. Deming, W. Zheng, W.-H. Xu, Q. Cai, Z. Ruan, Y.-B. Xiang, and X.-O. Shu
UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 563 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
S. M. Salih, S. A. Salama, M. Jamaluddin, A. A. Fadl, L. J. Blok, C. W. Burger, M. Nagamani, and A. Al-Hendy
Progesterone-Mediated Regulation of Catechol-O-Methyl Transferase Expression in Endometrial Cancer Cells
Reproductive Sciences, February 1, 2008; 15(2): 210 - 220.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
Y. Huang, S. V. Fernandez, S. Goodwin, P. A. Russo, I. H. Russo, T. R. Sutter, and J. Russo
Epithelial to Mesenchymal Transition in Human Breast Epithelial Cells Transformed by 17 -Estradiol
Cancer Res., December 1, 2007; 67(23): 11147 - 11157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Belous, D. L. Hachey, S. Dawling, N. Roodi, and F. F. Parl
Cytochrome P450 1B1-Mediated Estrogen Metabolism Results in Estrogen-Deoxyribonucleoside Adduct Formation
Cancer Res., January 15, 2007; 67(2): 812 - 817.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Tanaka, H. Hirata, Z. Chen, N. Kikuno, K. Kawamoto, S. Majid, T. Tokizane, S. Urakami, H. Shiina, K. Nakajima, et al.
Polymorphisms of Catechol-O-Methyltransferase in Men with Renal Cell Cancer
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 92 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. H. Tao, Q. Cai, W. H. Xu, N. Kataoka, W. Wen, W. Zheng, Y. B. Xiang, Z.-F. Zhang, and X. O. Shu
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Endometrial Cancer Risk in Chinese Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2570 - 2573.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Miyamoto, T. Shiozawa, H. Kashima, Y.-Z. Feng, A. Suzuki, M. Kurai, T. Nikaido, and I. Konishi
Estrogen Up-Regulates Mismatch Repair Activity in Normal and Malignant Endometrial Glandular Cells
Endocrinology, October 1, 2006; 147(10): 4863 - 4870.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Tsuchiya, M. Nakajima, S. Takagi, T. Taniya, and T. Yokoi
MicroRNA Regulates the Expression of Human Cytochrome P450 1B1.
Cancer Res., September 15, 2006; 66(18): 9090 - 9098.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. S. Crooke, M. D. Ritchie, D. L. Hachey, S. Dawling, N. Roodi, and F. F. Parl
Estrogens, enzyme variants, and breast cancer: a risk model.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1620 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. Russo, S. V. Fernandez, P. A. Russo, R. Fernbaugh, F. S. Sheriff, H. M. Lareef, J. Garber, and I. H. Russo
17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells
FASEB J, August 1, 2006; 20(10): 1622 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. R. Newbold, E. Padilla-Banks, and W. N. Jefferson
Adverse Effects of the Model Environmental Estrogen Diethylstilbestrol Are Transmitted to Subsequent Generations
Endocrinology, June 1, 2006; 147(6): s11 - s17.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Tanaka, M. Sasaki, H. Shiina, T. Tokizane, M. Deguchi, H. Hirata, Y. Hinoda, N. Okayama, Y. Suehiro, S. Urakami, et al.
Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 238 - 244.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. D. Yager and N. E. Davidson
Estrogen Carcinogenesis in Breast Cancer
N. Engl. J. Med., January 19, 2006; 354(3): 270 - 282.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Thibaudeau, J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al.
Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone
Cancer Res., January 1, 2006; 66(1): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Wellejus, A. Olsen, A. Tjonneland, B. L. Thomsen, K. Overvad, and S. Loft
Urinary Hydroxyestrogens and Breast Cancer Risk among Postmenopausal Women: A Prospective Study
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2137 - 2142.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tokizane, H. Shiina, M. Igawa, H. Enokida, S. Urakami, T. Kawakami, T. Ogishima, S. T. Okino, L.-C. Li, Y. Tanaka, et al.
Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5793 - 5801.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Kisselev, W.-H. Schunck, I. Roots, and D. Schwarz
Association of CYP1A1 Polymorphisms with Differential Metabolic Activation of 17{beta}-Estradiol and Estrone
Cancer Res., April 1, 2005; 65(7): 2972 - 2978.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Doherty, N. S. Weiss, R. J. Freeman, D. A. Dightman, P. J. Thornton, J. R. Houck, L. F. Voigt, M. A. Rossing, S. M. Schwartz, and C. Chen
Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 357 - 366.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Yoshida, S. Katashima, J. Ando, T. Tanaka, F. Uematsu, D. Nakae, and A. Maekawa
Dietary indole-3-carbinol promotes endometrial adenocarcinoma development in rats initiated with N-ethyl-N'-nitro-N-nitrosoguanidine, with induction of cytochrome P450s in the liver and consequent modulation of estrogen metabolism
Carcinogenesis, November 1, 2004; 25(11): 2257 - 2264.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
V K Turan, R I Sanchez, J J Li, S A Li, K R Reuhl, P E Thomas, A H Conney, M A Gallo, F C Kauffman, and S Mesia-Vela
The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17{beta}-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16{alpha}-hydroxyestradiol, and 4-hydroxyestrone
J. Endocrinol., October 1, 2004; 183(1): 91 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Tsuchiya, M. Nakajima, S. Kyo, T. Kanaya, M. Inoue, and T. Yokoi
Human CYP1B1 Is Regulated by Estradiol via Estrogen Receptor
Cancer Res., May 1, 2004; 64(9): 3119 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Duguay, M. McGrath, J. Lepine, J.-F. Gagne, S. E. Hankinson, G. A. Colditz, D. J. Hunter, M. Plante, B. Tetu, A. Belanger, et al.
The Functional UGT1A1 Promoter Polymorphism Decreases Endometrial Cancer Risk
Cancer Res., February 1, 2004; 64(3): 1202 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-M. Li, R. Todorovic, P. Devanesan, S. Higginbotham, H. Kofeler, R. Ramanathan, M. L. Gross, E. G. Rogan, and E. L. Cavalieri
Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo
Carcinogenesis, February 1, 2004; 25(2): 289 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. L. Hachey, S. Dawling, N. Roodi, and F. F. Parl
Sequential Action of Phase I and II Enzymes Cytochrome P450 1B1 and Glutathione S-Transferase P1 in Mammary Estrogen Metabolism
Cancer Res., December 1, 2003; 63(23): 8492 - 8499.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. C. Spink, B. H. Katz, M. M. Hussain, B. T. Pentecost, Z. Cao, and B. C. Spink
Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells
Carcinogenesis, December 1, 2003; 24(12): 1941 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. H. Conney
Enzyme Induction and Dietary Chemicals as Approaches to Cancer Chemoprevention: The Seventh DeWitt S. Goodman Lecture
Cancer Res., November 1, 2003; 63(21): 7005 - 7031.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sasaki, Y. Tanaka, M. Kaneuchi, N. Sakuragi, and R. Dahiya
CYP1B1 Gene Polymorphisms Have Higher Risk for Endometrial Cancer, and Positive Correlations with Estrogen Receptor {alpha} and Estrogen Receptor {beta} Expressions
Cancer Res., July 15, 2003; 63(14): 3913 - 3918.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. A. Leibelt, O. R. Hedstrom, K. A. Fischer, C. B. Pereira, and D. E. Williams
Evaluation of Chronic Dietary Exposure to Indole-3-Carbinol and Absorption-Enhanced 3,3'-Diindolylmethane in Sprague-Dawley Rats
Toxicol. Sci., July 1, 2003; 74(1): 10 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. R. Bianco, G. Perry, M. A. Smith, D. J. Templeton, and M. M. Montano
Functional Implications of Antiestrogen Induction of Quinone Reductase: Inhibition of Estrogen-Induced Deoxyribonucleic Acid Damage
Mol. Endocrinol., July 1, 2003; 17(7): 1344 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sasaki, M. Kaneuchi, N. Sakuragi, and R. Dahiya
Multiple Promoters of Catechol-O-methyltransferase Gene Are Selectively Inactivated by CpG Hypermethylation in Endometrial Cancer
Cancer Res., June 15, 2003; 63(12): 3101 - 3106.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P.-H. Lin, J. Nakamura, S. Yamaguchi, S. Asakura, and J. A. Swenberg
Aldehydic DNA lesions induced by catechol estrogens in calf thymus DNA
Carcinogenesis, June 1, 2003; 24(6): 1133 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. M. Samuni, E. Y. Chuang, M. C. Krishna, W. Stein, W. DeGraff, A. Russo, and J. B. Mitchell
Semiquinone radical intermediate in catecholic estrogen-mediated cytotoxicity and mutagenesis: Chemoprevention strategies with antioxidants
PNAS, April 29, 2003; 100(9): 5390 - 5395.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. E. Wyde, T. Cambre, M. Lebetkin, S. R. Eldridge, and N. J. Walker
Promotion of Altered Hepatic Foci by 2,3,7,8-Tetrachlorodibenzo-p-dioxin and 17{beta}-estradiol in Male Sprague-Dawley Rats
Toxicol. Sci., August 1, 2002; 68(2): 295 - 303.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Mesia-Vela, R. I. Sanchez, J. J. Li, S. A. Li, A. H. Conney, and F. C. Kauffman
Catechol estrogen formation in liver microsomes from female ACI and Sprague-Dawley rats: comparison of 2- and 4-hydroxylation revisited
Carcinogenesis, August 1, 2002; 23(8): 1369 - 1372.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
I. De Vivo, S. E. Hankinson, L. Li, G. A. Colditz, and D. J. Hunter
Association of CYP1B1 Polymorphisms and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 489 - 492.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Lavigne, J. E. Goodman, T. Fonong, S. Odwin, P. He, D. W. Roberts, and J. D. Yager
The Effects of Catechol-O-Methyltransferase Inhibition on Estrogen Metabolite and Oxidative DNA Damage Levels in Estradiol-treated MCF-7 Cells
Cancer Res., October 1, 2001; 61(20): 7488 - 7494.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. Yagi, J.C. Barrett, and T. Tsutsui
The ability of four catechol estrogens of 17{beta}-estradiol and estrone to induce DNA adducts in Syrian hamster embryo fibroblasts
Carcinogenesis, September 1, 2001; 22(9): 1505 - 1510.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Lee, J. W. Kosh, A. H. Conney, and B. T. Zhu
Characterization of the NADPH-Dependent Metabolism of 17beta -Estradiol to Multiple Metabolites by Human Liver Microsomes and Selectively Expressed Human Cytochrome P450 3A4 and 3A5
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. R. Newbold, E. P. Banks, B. Bullock, and W. N. Jefferson
Uterine Adenocarcinoma in Mice Treated Neonatally with Genistein
Cancer Res., June 1, 2001; 61(11): 4325 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. H. Hanna, S. Dawling, N. Roodi, F. P. Guengerich, and F. F. Parl
Cytochrome P450 1B1 (CYP1B1) Pharmacogenetics: Association of Polymorphisms with Functional Differences in Estrogen Hydroxylation Activity
Cancer Res., July 1, 2000; 60(13): 3440 - 3444.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newbold, R. R.
Right arrow Articles by Liehr, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newbold, R. R.
Right arrow Articles by Liehr, J. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online